Edition:
United States

People: GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,468.00GBp
21 Sep 2017
Change (% chg)

-- (--)
Prev Close
1,468.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
8,836,589
52-wk High
1,745.56
52-wk Low
1,444.00

Vallance, Patrick 

Mr. Patrick Vallance has been appointed as President - Pharmaceuticals R&D, Executive Director of Glaxosmithkline Plc, effective 1 January 2017. He joined CET in 2010 and was appointed President, Pharmaceuticals R&D, in January 2012. Prior to this he was Senior Vice President, Medicines Discovery and Development. Patrick joined the company in 2006 as Head of Drug Discovery. Prior to joining GSK Patrick was a clinical academic and led the Division of Medicine at University College London. He has over 20 years’ experience of research clinical medicine, general internal medicine, cardiovascular medicine and clinical pharmacology. He was elected to the Academy of Medical Sciences in 1999. Patrick has been on the Board of the UK Office for Strategic Co-ordination of Health Research (OSCHR) since 2009.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --